New Zealand - English - Medsafe (Medicines Safety Authority)

seqirus (nz) ltd - lacosamide 10 mg/ml - solution for injection - 200 mg/20ml - active: lacosamide 10 mg/ml excipient: hydrochloric acid sodium chloride water for injection - monotherapy in the treatment of partial seizures with or without secondary generalisation in patients with epilepsy aged 16 years and older. add-on therapy in the treatment of partial seizures with or without secondary generalisation in patients with epilepsy aged 4 years and older. vimpat (lacosamide) injection for intravenous infusion is indicated when oral administration is temporarily not feasible. add-on therapy in the treatment of primary generalised tonic-clonic seizures in patients with idiopathic generalised epilepsy aged 4 years and older.

Canada - English - Health Canada

novopharm limited - doxorubicin hydrochloride - solution - 2mg - doxorubicin hydrochloride 2mg - antineoplastic agents

Canada - English - Health Canada

sandoz canada incorporated - doxorubicin hydrochloride - solution - 2mg - doxorubicin hydrochloride 2mg - antineoplastic agents

Canada - English - Health Canada

omega laboratories limited - doxorubicin hydrochloride - solution - 2mg - doxorubicin hydrochloride 2mg - antineoplastic agents

Canada - English - Health Canada

strides pharma canada inc - doxorubicin hydrochloride - solution - 2mg - doxorubicin hydrochloride 2mg - antineoplastic agents

Canada - English - Health Canada

panda pharmaceuticals inc. - doxorubicin hydrochloride - powder for solution - 50mg - doxorubicin hydrochloride 50mg - antineoplastic agents

Australia - English - Department of Health (Therapeutic Goods Administration)

ucb australia pty ltd t/a ucb pharma division of ucb australia - lacosamide, quantity: 10 mg/ml - injection, solution - excipient ingredients: water for injections; sodium chloride; dilute hydrochloric acid - vimpat (lacosamide) injection for intravenous infusion is indicated as:,? monotherapy in the treatment of partial-onset seizures with or without secondary generalisation in patients with epilepsy aged 16 years and older.,? add-on therapy in the treatment of partial-onset seizures with or without secondary generalisation in patients with epilepsy aged 4 years and older.,? add-on therapy in the treatment of primary generalised tonic-clonic seizures in patients with idiopathic generalised epilepsy aged 4 years and older.,vimpat (lacosamide) injection for intravenous infusion is indicated when oral administration is temporarily not feasible.

Australia - English - Department of Health (Therapeutic Goods Administration)

ucb australia pty ltd t/a ucb pharma division of ucb australia - lacosamide, quantity: 200 mg - tablet, film coated - excipient ingredients: hyprolose; crospovidone; microcrystalline cellulose; colloidal anhydrous silica; magnesium stearate; titanium dioxide; purified talc; polyvinyl alcohol; macrogol 3350; indigo carmine aluminium lake - vimpat (lacosamide) tablets and oral solution are indicated as:,? monotherapy in the treatment of partial-onset seizures with or without secondary generalisation in patients with epilepsy aged 16 years and older.,? add-on therapy in the treatment of partial-onset seizures with or without secondary generalisation in patients with epilepsy aged 4 years and older.,? add-on therapy in the treatment of primary generalised tonic-clonic seizures in patients with idiopathic generalised epilepsy aged 4 years and older.

Australia - English - Department of Health (Therapeutic Goods Administration)

ucb australia pty ltd t/a ucb pharma division of ucb australia - lacosamide, quantity: 150 mg - tablet, film coated - excipient ingredients: hyprolose; microcrystalline cellulose; crospovidone; magnesium stearate; colloidal anhydrous silica; titanium dioxide; purified talc; iron oxide yellow; iron oxide red; polyvinyl alcohol; macrogol 3350; iron oxide black - vimpat (lacosamide) tablets and oral solution are indicated as:,? monotherapy in the treatment of partial-onset seizures with or without secondary generalisation in patients with epilepsy aged 16 years and older.,? add-on therapy in the treatment of partial-onset seizures with or without secondary generalisation in patients with epilepsy aged 4 years and older.,? add-on therapy in the treatment of primary generalised tonic-clonic seizures in patients with idiopathic generalised epilepsy aged 4 years and older.

Australia - English - Department of Health (Therapeutic Goods Administration)

ucb australia pty ltd t/a ucb pharma division of ucb australia - lacosamide, quantity: 100 mg - tablet, film coated - excipient ingredients: colloidal anhydrous silica; hyprolose; microcrystalline cellulose; crospovidone; magnesium stearate; titanium dioxide; purified talc; iron oxide yellow; polyvinyl alcohol; macrogol 3350 - vimpat (lacosamide) tablets and oral solution are indicated as:,? monotherapy in the treatment of partial-onset seizures with or without secondary generalisation in patients with epilepsy aged 16 years and older.,? add-on therapy in the treatment of partial-onset seizures with or without secondary generalisation in patients with epilepsy aged 4 years and older.,? add-on therapy in the treatment of primary generalised tonic-clonic seizures in patients with idiopathic generalised epilepsy aged 4 years and older.